Kalvista Pharmaceuticals Stock Price, Forecast & Analysis (NASDAQ:KALV)

Kalvista Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALV."

Kalvista Pharmaceuticals Inc (NASDAQ:KALV) released its quarterly earnings results on Monday, September, 9th. The specialty pharmaceutical company reported ($0.42) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.62) by $0.20. The specialty pharmaceutical company earned $3.37 million during the quarter, compared to analyst estimates of $3.24 million. Kalvista Pharmaceuticals had a negative return on equity of 22.29% and a negative net margin of 144.64%. View Kalvista Pharmaceuticals' Earnings History.

Kalvista Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, December 13th 2019. View Earnings Estimates for Kalvista Pharmaceuticals.

5 Wall Street analysts have issued 1-year price targets for Kalvista Pharmaceuticals' stock. Their forecasts range from $30.00 to $35.00. On average, they expect Kalvista Pharmaceuticals' stock price to reach $31.80 in the next twelve months. This suggests a possible upside of 187.3% from the stock's current price. View Analyst Price Targets for Kalvista Pharmaceuticals.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kalvista Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kalvista Pharmaceuticals.

News stories about KALV stock have been trending very negative this week, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Kalvista Pharmaceuticals earned a coverage optimism score of -3.0 on InfoTrie's scale. They also assigned press coverage about the specialty pharmaceutical company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days. View News Stories for Kalvista Pharmaceuticals.

Kalvista Pharmaceuticals saw a decline in short interest in October. As of October 31st, there was short interest totalling 734,400 shares, a decline of 10.9% from the September 30th total of 824,300 shares. Based on an average daily trading volume, of 121,300 shares, the days-to-cover ratio is presently 6.1 days. Approximately 5.8% of the company's shares are sold short. View Kalvista Pharmaceuticals' Current Options Chain.

Some companies that are related to Kalvista Pharmaceuticals include Eagle Pharmaceuticals (EGRX), CannTrust (CNTTF), TherapeuticsMD (TXMD), Organogenesis (ORGO), Rocket Pharmaceuticals (RCKT), Omeros (OMER), Revance Therapeutics (RVNC), Kura Oncology (KURA), ANI Pharmaceuticals (ANIP), Collegium Pharmaceutical (COLL), Flexion Therapeutics (FLXN), Homology Medicines (FIXX), Emisphere Technologies (EMIS), Viking Therapeutics (VKTX) and Akero Therapeutics (AKRO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kalvista Pharmaceuticals investors own include Heron Therapeutics (HRTX), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), Corbus Pharmaceuticals (CRBP), GALAPAGOS NV/S (GLPG), Ritter Pharmaceuticals (RTTR), Viking Therapeutics (VKTX), Brainstorm Cell Therapeutics (BCLI), BIOLINERX LTD/S (BLRX) and Progenics Pharmaceuticals (PGNX).

Kalvista Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Tower Research Capital LLC TRC (0.02%). Company insiders that own Kalvista Pharmaceuticals stock include Albert Cha, Andreas Maetzel, Benjamin L Palleiko, Christopher Yea, Daniel B Soland, Edward P Feener, Life Sciences Fund Iv (Gp) Sv, Svlsf Iv, Llc, Thomas Andrew Crockett and Venrock Healthcare Capital Par. View Institutional Ownership Trends for Kalvista Pharmaceuticals.

KALV stock was bought by a variety of institutional investors in the last quarter, including Tower Research Capital LLC TRC . Company insiders that have bought Kalvista Pharmaceuticals stock in the last two years include Albert Cha and Daniel B Soland. View Insider Buying and Selling for Kalvista Pharmaceuticals.

Shares of KALV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KALV stock can currently be purchased for approximately $11.07.

Kalvista Pharmaceuticals has a market capitalization of $197.27 million and generates $16.13 million in revenue each year. The specialty pharmaceutical company earns $-20,820,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis. Kalvista Pharmaceuticals employs 33 workers across the globe.View Additional Information About Kalvista Pharmaceuticals.

The official website for Kalvista Pharmaceuticals is http://www.kalvista.com/.

Kalvista Pharmaceuticals' mailing address is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. The specialty pharmaceutical company can be reached via phone at 857-999-0075 or via email at [email protected]